Drugs / LEZ763
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01619332 | Mar 2012 → Sep 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEZ763 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01619332 ↗ |
| Route | Oral | “LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner” NCT01619332 ↗ |